ophthalmologytimes7h
European Commission grants marketing authorization to aflibercept biosimilar from Sandoz Group
Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
PharmiWeb8h
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...
The Korea Bizwire14h
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...
The Financial Express17h
European Commission grants approval to Sandoz’s biosimilar to treat retinal diseases
Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...